Maverex posters at ISPOR Copenhagen 2019

It’s that time of the year again, and the Maverex team is delighted to be attending ISPOR Europe in Copenhagen! As well as enjoying the beautiful city, we are keen to be there for presentations and discussions on the latest in determining value in healthcare and to catch up with friends and colleagues.

We are also very excited that this year’s ISPOR theme is digital transformation of healthcare. As a company with a keen focus on digital innovation, we are looking forward to some interesting debates on how digital solutions can help improve the way healthcare businesses interact with regulators, healthcare providers, and patients.

This year we are presenting a range of topical and varied posters that reflect some of the work we have been conducting over the last few months:

• THE PATIENT PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS FOR ORPHAN DRUGS ACROSS DIFFERENT COUNTRIES
  Our value communication team are often involved in developing materials to demonstrate the value of treatments for rare diseases, which can be challenging due to the limited availability of evidence describing disease burden and unmet need, and because the impact of treatment on patients’ day-to-day lives may not be fully captured in clinical trials. The patient (or carer) perspective is therefore key in these situations. To better understand how patient/carer input is being used in HTAs of orphan drugs, we looked at HTAs of 22 recently licenced orphan drugs from Australia, Canada, England, and Scotland. We found a variety of different types of patient input across the countries. However, despite a generally positive association between patient input and decision making, the impact on final HTA decisions remains unclear.

• THE INCREASING USE AND ACCEPTANCE OF ALTERNATIVE STATISTICAL APPROACHES TO INDIRECT COMPARISON IN THE NATIONAL INSTITUTE OF HEALTH AND CARE EXCELLENCE (NICE) HEALTH TECHNOLOGY ASSESSMENT (HTA) SUBMISSION PROCESS
  Inspired by our frequent involvement in developing ITCs for HTA, we investigated the use and acceptance of alternative statistical techniques for indirect comparisons in NICE technology appraisals. We found that the prevalence and acceptance of alternatives such as matching-adjusted indirect comparisons (MAIC) has increased over time, particularly in the area of oncology where often only single arm Phase II data is available.

• COST-CONSEQUENCES ANALYSIS OF PAEDIATRIC TRIPLE-CHAMBER-BAGS (3CBS) IMPACT ON HOSPITAL RESOURCES AND CLINICAL OUTCOMES IN PRETERM NEONATES ACROSS BELGIUM, PORTUGAL, SPAIN AND THE UK
  In this cost-consequences analysis, developed with our collaborators, we demonstrated the impact the use of paediatric triple-chamber-bags (3CBS) has on hospital resources and clinical outcomes. Triple-chamber-bags are off-the-shelf manufactured parenteral nutrient bags containing well defined macro-nutrients. We found that a 10% increase in their use for preterm neonates could have significant benefits for patient health, healthcare professional time, and hospital cost-saving.

• THERAPEUTIC BENEFIT OF ORPHAN DRUGS IN ONCOLOGY: EVIDENCE AT THE POINT OF EUROPEAN MARKETING AUTHORISATION
  Together with our partners at Apogenix AG, we analysed the therapeutic benefit of orphan drugs for oncology at the point they were authorised for European marketing by the EMA. This study discusses the need for adaptive approaches for evidence generation, as demonstration of therapeutic benefit via RCTs is not always feasible in rare oncology.

If you’d like to find out more about any of our research, please get in touch at enquiries@maverex.com, or come and meet us at ISPOR Booth C3-058.